3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
27
Cisplatin
24
pembrolizumab
15
durvalumab
12
Fluorouracil
11
Capecitabine
10
Oxaliplatin
9
Leucovorin
8
Bevacizumab
7
Carboplatin
5
Paclitaxel
4
Nivolumab
4
Irinotecan
4
Injections
4
zanidatamab
3
trametinib
3
lenvatinib
3
derazantinib
3
atezolizumab
3
Ramucirumab
3
Docetaxel
3
tremelimumab
2
surufatinib
2
pertuzumab
2
gemcitabine-oxaliplatin regimen
2
envafolimab
2
Trastuzumab
2
S 1 (combination)
2
Itraconazole
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biliary Tract Neoplasms
×
AZD5305
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled